Therapy Optimisation for the Treatment of Hairy Cell Leukemia

The trial will test the effectiveness and toxicity of subcutaneous treatment with one cycle of cladribine in patients with hairy cell leukemia requiring treatment. They have to be untreated so far or may be pretreated with alpha-interferon.

Trial Details

NCT ID

NCT02131753

Phase

PHASE2 / PHASE3

Sponsor

University of Giessen

Status

RECRUITING

Cancer Type

Hairy Cell Leukemia Leukemia

Interventions

Cladribine s.c. injection, HCL treatment

Locations (sample)

Ansbach, Germany|49.30481,10.5931
Aschaffenburg, Germany|49.97704,9.15214
Bad Neustadt an der Saale, Germany|50.32174,10.20673
Berlin, Germany|52.52437,13.41053
Bremen, Germany|53.07582,8.80717

Key Eligibility Criteria

Patients with histologically verified hairy cell leukemia
Presence of hairy cells in the bone marrow and peripheral blood detected by positive TRAP staining and / or co expression if cell surface antigens …
No previous cytostatic treatment (splenectomy or interferon treatment are allowed)
Need for treatment

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Hairy Cell Leukemia Leukemia Trials on Trialify →